S'abonner

Incidence and predictors of atrial fibrillation episodes as detected by implantable loop recorder in patients at risk: From the LOOP study - 18/12/19

Doi : 10.1016/j.ahj.2019.09.009 
Søren Zöga Diederichsen, MD a, , Ketil Jørgen Haugan, MD, PhD b, Axel Brandes, MD, DMSc c, d, Claus Graff, PhD e, Derk Krieger, MD, PhD f, g, Christian Kronborg, PhD h, Anders Gaarsdal Holst, MD, PhD i, Jonas Bille Nielsen, MD, PhD i, j, k, Lars Køber, Md, DMSc a, l, Søren Højberg, MD, PhD m, Jesper Hastrup Svendsen, Md, DMSc a, i, l
a Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark 
b Department of Cardiology, Sjaelland University Hospital Roskilde, Sygehusvej 10, Roskilde, Denmark 
c Department of Cardiology, Odense University Hospital, J. B. Winsløws Vej 4, Odense, Denmark 
d Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Winsløwparken 19, Odense C, Denmark 
e Department of Health Science and Technology, Aalborg University, Fredrik Bajers Vej 7 D2, Aalborg, Denmark 
f University Hospital Zurich, University of Zurich, Rämistrasse 100, Zürich, Switzerland 
g Stroke Unit, Mediclinic City Hospital, Building 37 - 26th St, Dubai, UAE 
h Department of Business and Economics, University of Southern Denmark, Campusvej 55, Odense, Denmark 
i Laboratory for Molecular Cardiology, Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark 
j Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark 
k K.G. Jebsen Center for Genetic Epidemiology, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Håkon Jarls Gate 11, Trondheim, Norway 
l Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, Copenhagen, Denmark 
m Department of Cardiology, Bispebjerg Hospital, Copenhagen University Hospital, Bispebjerg Bakke 23, Copenhagen, Denmark 

Reprint requests: Søren Zöga Diederichsen, MD, Department of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 København, Denmark.Department of CardiologyThe Heart Centre, Rigshospitalet, Copenhagen University HospitalBlegdamsvej 9København2100Denmark

Abstract

Background

Recent studies have suggested a high prevalence of subclinical atrial fibrillation (AF) in various patient populations, and interest in AF screening has increased. However, knowledge about episode duration is scarce, and risk factors for short or long subclinical AF episodes have yet to be recognized. The aim of the study was to assess AF by long-term continuous screening and to investigate predictors of episodes lasting ≥6 minutes, ≥5.5 hours, or ≥24 hours, respectively.

Methods

A total of 597 patients aged ≥70 years and diagnosed with ≥1 of hypertension, diabetes, previous stroke, or heart failure were recruited from the general population to receive implantable loop recorder with remote monitoring. Exclusion criteria included history of AF or cardiac implantable electronic device. AF episodes were adjudicated by senior cardiologists.

Results

During 40 (37; 42) months of continuous monitoring, AF was detected in 209 (35%) of the patients. The cumulative incidences at 3 years were 33.8% (30.2%-37.8%), 16.1% (13.4%-19.4%), and 5.7% (4.1%-7.9%) for AF episodes lasting ≥6 minutes, ≥5.5 hours, and ≥24 hours, respectively. Slower resting sinus rate and higher body mass index, N-terminal prohormone of brain natriuretic peptide, and troponin T at baseline were independently associated with AF detection. Addition of these markers to a model of sex, age, and comorbidities improved prediction of AF episodes ≥24 hours (time-dependent area under the receiver operating characteristic curve 79% vs 65%, P = .037).

Conclusions

A considerable burden of previously unknown AF was detected when long-term monitoring was applied in at-risk patients. Biomarkers were associated with AF incidence and improved prediction of long AF episodes.

Le texte complet de cet article est disponible en PDF.

Plan


© 2019  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 219

P. 117-127 - janvier 2020 Retour au numéro
Article précédent Article précédent
  • Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease—A meta-analysis of randomized clinical trials
  • Salvatore Cassese, Gjin Ndrepepa, Robert A. Byrne, Karl-Ludwig Laugwitz, Heribert Schunkert, Massimiliano Fusaro, Fernando Alfonso, Adnan Kastrati
| Article suivant Article suivant
  • Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study
  • James A. Reiffel, Atul Verma, Peter R. Kowey, Jonathan L. Halperin, Bernard J. Gersh, Mitchell S.V. Elkind, Paul D. Ziegler, Rachelle E. Kaplon, Lou Sherfesee, Rolf Wachter, REVEAL AF Investigators

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.